Related Experiment Videos
Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells
Fred Penninkhof1, J Anton Grootegoed, Leen J Blok
1Department of Reproduction and Development, Erasmus MC, Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
Abstract:
The protein REPS2 is implicated in growth factor receptor-mediated endocytosis and signalling, and its expression is downregulated in androgen-independent prostate cancer cells. Herein, the NF-kappaB subunit p65 is identified as a human REPS2 protein partner, interacting with the EH domain of REPS2. Using crystal structure data from literature and experimental data from yeast and mammalian two-hybrid analysis, the results indicate that the NPF-motif in p65 acts as binding site for the EH domain in REPS2. However, in cultured prostate cancer cells, the REPS2-p65 interaction is triggered upon stimulation with phorbol ester (PMA). This indicates that PMA-sensitive signalling pathways can affect the interaction between REPS2 and p65. During prostate cancer progression from androgen-dependent to androgen-independent growth, downregulation of REPS2 is accompanied by upregulation of NF-kappaB activity. This might involve loss of REPS2-p65 interaction, which would lead to increased NF-kappaB activity. Androgen-deprivation causes apoptosis of prostate cancer cells, and activated NF-kappaB is a known inhibitor of apoptosis. Hence, decreased expression of REPS2 might be a key factor, causing prostate cancer cells to become resistant to induction of apoptosis by androgen deprivation.
Insights
Researchers found that the protein REPS2 interacts with NF-kappaB subunit p65. Decreased REPS2 in prostate cancer may lead to increased NF-kappaB activity, promoting resistance to apoptosis during disease progression.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- REPS2 protein is involved in endocytosis and signaling pathways.
- REPS2 expression decreases in androgen-independent prostate cancer.
- NF-kappaB signaling is upregulated during prostate cancer progression.
Purpose of the Study:
- To identify REPS2 interacting partners.
- To investigate the functional consequences of REPS2 downregulation in prostate cancer.
Main Methods:
- Yeast and mammalian two-hybrid assays.
- Analysis of crystal structure data.
- Cell culture and stimulation with phorbol ester (PMA).
Main Results:
- NF-kappaB subunit p65 identified as a REPS2 interacting partner.
- The NPF-motif in p65 binds to the EH domain of REPS2.
- REPS2-p65 interaction is sensitive to PMA stimulation.
- REPS2 downregulation correlates with increased NF-kappaB activity in advanced prostate cancer.
Conclusions:
- Loss of REPS2-p65 interaction may contribute to increased NF-kappaB activity.
- Decreased REPS2 expression could drive resistance to apoptosis in prostate cancer cells.
- REPS2 downregulation is a potential mechanism for androgen-independent growth and therapeutic resistance.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Abnormal Proliferation
Regulation of Nuclear Protein Sorting
Co-activators and Co-repressors
Negative Regulator Molecules